Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, today announced the issuance of Australian patent no. 61/057,713 covering the use of Eltoprazine for the treatment of various neurological and mental disorders, including Parkinson’s disease, Alzheimer’s disease and several other mental disorders.
“This patent issuance covering Eltoprazine for the treatment of Parkinson’s disease and Alzheimer’s disease represents a significant addition to the international intellectual property position covering Eltoprazine,” said Gerald E. Commissiong, President & CEO of Amarantus. “As the company evaluates business development opportunities, we believe the continued expansion of the patent estate covering Eltoprazine will be important.”
Read more more at: http://globenewswire.com
